148 related articles for article (PubMed ID: 22490898)
1. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
Lin J; Wang YH; Zhang YH; Tian Y
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):388-91. PubMed ID: 22490898
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.
Liu C; Schreiter T; Frilling A; Dahmen U; Broelsch CE; Gerken G; Treichel U
World J Gastroenterol; 2005 Dec; 11(48):7602-5. PubMed ID: 16437685
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
Voisard R; Geçgüner L; Baur R; Herter T; Hombach V
Int J Cardiol; 2005 Jul; 102(3):435-42. PubMed ID: 16004888
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P
Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
Kaczmarek I; Zaruba MM; Beiras-Fernandez A; Reimann R; Nickel T; Grinninger C; Sadoni S; Hagl C; Meiser B
J Heart Lung Transplant; 2013 Mar; 32(3):277-84. PubMed ID: 23415313
[TBL] [Abstract][Full Text] [Related]
8. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
[TBL] [Abstract][Full Text] [Related]
9. Marked erythrocyte microcytosis under primary immunosuppression with sirolimus.
Kim MJ; Mayr M; Pechula M; Steiger J; Dickenmann M
Transpl Int; 2006 Jan; 19(1):12-8. PubMed ID: 16359372
[TBL] [Abstract][Full Text] [Related]
10. Liver pathology and cell proliferation after calcineurin inhibitors and antiproliferative drugs following partial hepatectomy in rats.
Kirimlioglu H; Kirimlioglu V; Yilmaz S; Coban S; Turkmen E; Ara C
Transplant Proc; 2006 Mar; 38(2):622-6. PubMed ID: 16549191
[TBL] [Abstract][Full Text] [Related]
11. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM
Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413
[TBL] [Abstract][Full Text] [Related]
12. Can we eliminate both calcineurin inhibitors and steroids?
Lebranchu Y
Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
[TBL] [Abstract][Full Text] [Related]
13. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood.
Barten MJ; Dhein S; Chang H; Bittner HB; Tarnok A; Rahmel A; Mohr FW; Gummert JF
J Immunol Methods; 2003 Dec; 283(1-2):99-114. PubMed ID: 14659903
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil attenuates Walker's tumor growth when used alone, but the effect is lost when associated with cyclosporine.
Silva SL; Silva SF; Cavalcante RO; Mota RS; Carvalho RA; Moraes MO; Campos HH; Moraes ME
Transplant Proc; 2004 May; 36(4):1004-6. PubMed ID: 15194349
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
Huang H; Zheng W; Lin M; Fu J; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
[TBL] [Abstract][Full Text] [Related]
17. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
Berry V; Magill A; Yost M; Janosky J; Sindhi R
Cytometry A; 2006 Feb; 69(2):95-103. PubMed ID: 16369935
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor.
Vuiblet V; Birembaut P; François A; Cordonnier C; Noel LH; Goujon JM; Paraf F; Machet MC; Girardot-Seguin S; Lebranchu Y; Rieu P
Nephrol Dial Transplant; 2012 Jan; 27(1):411-6. PubMed ID: 21617191
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Transplantation; 2004 Mar; 77(5):683-6. PubMed ID: 15021829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
